• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Isentress (raltegravir potassium) 400 mg tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – November 2009

 

Summary View

 

ADVERSE REACTIONS

Postmarketing Experience
  • Blood and Lymphatic System Disorders: thrombocytopenia

PATIENT PACKAGE INSERT

What are the possible side effects of Isentress?
  • Other: low blood platelet count